Oncology Health Economic Modeling Post-Progression Working Group
Ágnes Benedict, MSc, BSc
Senior Research Scientist
Evidera, Inc.
Budapest, Hungary
Khalid Kamal, M.Pharm, PhD
Associate Professor,
Pharmacy Administration
Mylan School of Pharmacy
Duquesne University
Pittsburgh, PA, USA
Noémi Muszbek, MSc, BSc
Senior Research Scientist
Evidera, Inc.
England, UK
Leadership Group

Raquel Aguiar-Ibáñez, MSc, BEc, Senior HTA & OR Manager, MSD, Hoddesdon, England, UK
Kathi Apostolidis, Vice President, European Cancer Patient Coalition (ECPC), Brussels, Belgium
Nermeen Ashoush, MSc, Lecturer in Clinical Pharmacy and Clinic, British University in Egypt, Cairo, Egypt
Seungjin Bae, RPh, ScD, Assistant Professor, Ewha Womans University, College of Pharmacy, Seoul, South Korea
Marissa Betts, MS, Senior Research Associate, Evidera, Lexington, MA, USA
Elizabeth Cahn, PhD, Patient Advocate, Dana-Farber/Harvard Cancer Center Breast Cancer Advocacy Group, Boston, MA, USA
Manjusha Hurry, MSc, BSc, BA, Senior Manager, Health Economics (Oncology), AstraZeneca Canada, Mississauga, ON, Canada
Rémi Marty, PharmD, MSc, Health Economist, Belgium
Chad Patel, PharmD, Field Director, HEOR, Bristol Myers Squibb, Chicago, IL, USA
Xavier Pouwels, MSc, Junior Researcher, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands
James Ryan, MSc, BA, Oncology Group Director, Health Economics and Payer Analytics, AstraZeneca Global, Cambridge, England, UK
Bettina Ryll, MD, PhD, Founder, Melanoma Patient Network Europe, Uppsala, Sweden
John W. Stevens, PhD, BSc, Reader in Decision Science, ScHARR, The University of Sheffield, Sheffield, England, UK
Sorrel Wolowacz, PhD, Head, EU Health Economics, RTI Health Solutions, Manchester, England, UK

Student Researchers


This working group aims to facilitate the development and adoption of improved oncology modeling methods by reviewing the recent use of utilities, disease management, and treatment pattern data in cancer models; highlighting the lack of information regarding data post-progression/post-response in cancer; and advancing the knowledge & understanding around oncology modeling by fostering a multidisciplinary collaboration including clinicians and patient representatives.


Health policy surrounding the reimbursement of cancer treatments has received a lot of attention in recent years, not only from reimbursement and health technology assessment (HTA) bodies and health economics and outcomes researchers, but also from the clinical community and the general public. Substantial investment in fundamental and clinical research has led to the development of numerous new treatment modalities such as immunotherapies and personalized medicine approaches. The growing global market and increasing price of new oncology drugs has focused the attention of HTA bodies on oncology treatments and the clinical community has recognized the need to assess the value of cancer treatment options. This has resulted in the development of new guidelines and new technology appraisal arrangements (e.g. the pan-Canadian Oncology Drug Review (pCODR) in Canada and the National Institute for Health and Care Excellence (NICE) end of life criteria in the UK).

The increasing attention on assessing the value of oncology products has resulted in close scrutiny of HTA methods, and of the validity of health economic models evaluating the cost-effectiveness of new interventions. Research is ongoing in the health economic and outcomes research (HEOR) community to address the various methodological challenges in health economic modeling in oncology, questioning current methods and developing new guidelines, methods and approaches.


Methods and Preliminary Results of the ISPOR Oncology Health Economic Modeling Special Interest Group
November 2017 – ISPOR 20th Annual European Congress, Forum, Glasgow, Scotland, UK

Health Economic Modeling in Oncology
May 2017 – ISPOR 22nd Annual International Meeting, Forum, Boston, MA, USA

Oncology Health Economic Modeling Post- Progression Working Group of the ISPOR Oncology SIG
November 2016 – ISPOR 19th Annual European Congress, Forum, Vienna, Austria

ISPOR Health Economic Modeling in Oncology Special Interest Group
November 2015 - ISPOR 18th Annual European Congress, Open Meeting, Milan, Italy

Work Products:

Two manuscripts to be submitted to Value in Health:

  1. "Modeling changes in utilities after disease progression or towards the end of life"
  2. "Modeling changes in disease management costs and treatment patterns after disease progression or towards the end of life"
Work product timeline:



SIG project initiated

December 2015

Members solicited to work on project

January 2016

Literature review protocol, searches and screening March 2016 – January 2018
SIG meeting at ISPOR DC May 24, 2016
Forum at ISPOR Vienna November 1, 2016
Presentation at ISPOR Boston May 2017
Presentation at ISPOR Glasgow November 2017
Literature review: data extraction January – April 2018
Assign sections of the manuscript to the SIG leadership members April – May 2018
Develop manuscript sections May – October 2018
Group approves draft to be sent out for review November 2018
Revised manuscript sent to ISPOR SIG Review Group (members interested in the topic) December 2018
Review comments from ISPOR SIG Review Group February 2019
Authors revise sections March – April 2019
Second review to ISPOR SIG Review Group April 2019
Members and co-chairs finalize and sign off on final report August 2019
Manuscript submitted to Value in Health September 2019


Leadership Group Members Only

How to login

User name: first part of the email address (before @)
(e.g. for it should be jdoe)

Password: ISPOR Member ID.

Click here for login help

To join this SIG Working Group, see: Join a Special Interest Group.

Oncology SIG | Special Interest Groups Index